

March 3, 2017

DCAT TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

DCAT
WEEK
2017

OPENING DAY

HAPPY
HOUR


Request an invitation

1. [Merck Takes \\$2.9-Billion Write-Down on Hep C Drug Candidate](#)

Merck & Co. is taking a \$2.9-billion impairment charge on a hepatitis C drug candidate that the company gained through its \$3.85-billion acquisition of Idenix Pharmaceuticals in 2014 based on a lower than expected valuation of the drug. [Read More](#)

2. [Endo Takes \\$3.5-Billion Write-Down on US Generics Decline](#)

Endo has taken \$3.5 billion in asset impairment charges, largely due to a decline in its US generics business, which is facing increased pricing pressure and competition. [Read More](#)

3. [Perrigo Cuts 750 Jobs in Cost-Saving Strategy...](#)

Perrigo is reducing its global workforce by 750 employees, or 14% of the company's global workforce, as part of a cost-cutting strategy the company is implementing. [Read More](#)

4. [...and Divests MS Drug Royalty Stream in \\$2.85-Billion Deal](#)

Perrigo is divesting its rights to the royalty stream from global net sales of Tysabri (natalizumab), Biogen's multiple sclerosis drug, to RPI Finance Trust, an affiliate of Royalty Pharma, in a deal valued at up to \$2.85 billion. Tysabri, a blockbuster drug for Biogen, had 2016 sales of \$1.96 billion. [Read More](#)

5. [Sanofi, Lonza Partner on \\$290-Million Biologics Manufacturing Facility](#)

Sanofi and Lonza have partnered in a joint venture to build and operate a large-scale mammalian cell culture facility for manufacturing monoclonal antibodies at Lonza's site in Visp, Switzerland, with an initial investment of CHF 290 million (\$289 million), to be split equally between each company. The facility is expected to begin operations by 2020. [Read More](#)

6. [Novo Nordisk Appoints SVP North America as EVP Departs](#)

Novo Nordisk has appointed Doug Langa as senior vice president, head of North America Operations and president of Novo Nordisk Inc. following the resignation of Jakob Riis, executive vice president, head of North America Operations and president of Novo Nordisk Inc. [Read More](#)

7. [Lilly Completes \\$960-Million Buy of Migraine Drug Company](#)

Eli Lilly and Company has completed its previously announced \$960-million acquisition of CoLucid

Pharmaceuticals, a biopharmaceutical company focused on migraine therapies. The acquisition boosts Lilly's existing portfolio in pain management for migraine. [Read More](#)

8. [Takeda Transfers CMC Business to CMO Partner](#)

Takeda has formed a partnership with Bushu Pharmaceuticals Limited, a CMO, which will take on a part of Takeda's pharmaceutical sciences/chemistry, manufacturing, and controls (CMC) business. Bushu will deliver on process chemistry, formulation, and analytical development as well as develop and manufacture clinical trial materials. [Read More](#)

9. [Recipharm Completes \\$120-Million Kemwell Indian Biz Acquisition](#)

Recipharm has completed its previously announced acquisition of Kemwell's pharmaceutical business, Recipharm Pharmaservices Private Ltd, located in Bangalore, India, for Indian rupee 7.98 billion (\$120 million). [Read More](#)

10. [FDA, EC in Pact for Pharma Manufacturing Facility Inspections](#)

The FDA and European Commission have agreed that US and EU regulators will be able to use each other's good manufacturing practice inspections of pharmaceutical manufacturing facilities in an effort to eliminate duplication of drug inspections and lower inspection costs. [Read More](#)

[DCAT Week '17: Pfizer, AstraZeneca, and Kite Pharma Discuss Biomanufacturing](#)

As pharmaceutical companies intensify their product development in biologics, their supply requirements increase as well. The DCAT Week '17 education program, [Biomanufacturing 2017: Capacity, Investment, and Technology](#), provides insight from Pfizer, AstraZeneca, and Kite Pharma on the near-term and future direction of biomanufacturing. [Read More](#)

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcac.org